119 related articles for article (PubMed ID: 9492077)
1. Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism.
Masarachia P; Yamamoto M; Leu CT; Rodan G; Duong L
Endocrinology; 1998 Mar; 139(3):1401-10. PubMed ID: 9492077
[TBL] [Abstract][Full Text] [Related]
2. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats.
Yamamoto M; Fisher JE; Gentile M; Seedor JG; Leu CT; Rodan SB; Rodan GA
Endocrinology; 1998 Mar; 139(3):1411-9. PubMed ID: 9492078
[TBL] [Abstract][Full Text] [Related]
3. Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells.
Nakamura I; Tanaka H; Rodan GA; Duong LT
Endocrinology; 1998 Dec; 139(12):5182-93. PubMed ID: 9832459
[TBL] [Abstract][Full Text] [Related]
4. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.
Nakamura I; Pilkington MF; Lakkakorpi PT; Lipfert L; Sims SM; Dixon SJ; Rodan GA; Duong LT
J Cell Sci; 1999 Nov; 112 ( Pt 22)():3985-93. PubMed ID: 10547359
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.
Fisher JE; Caulfield MP; Sato M; Quartuccio HA; Gould RJ; Garsky VM; Rodan GA; Rosenblatt M
Endocrinology; 1993 Mar; 132(3):1411-3. PubMed ID: 8440195
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies of the s-echistatin inhibition of bone resorption.
Sato M; Garsky V; Majeska RJ; Einhorn TA; Murray J; Tashjian AH; Gould RJ
J Bone Miner Res; 1994 Sep; 9(9):1441-9. PubMed ID: 7817829
[TBL] [Abstract][Full Text] [Related]
7. Morphological and ultrastructural aspects of the activation of avian medullary bone osteoclasts by parathyroid hormone.
Miller SC; Bowman BM; Myers RL
Anat Rec; 1984 Feb; 208(2):223-31. PubMed ID: 6703339
[TBL] [Abstract][Full Text] [Related]
8. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.
Carron CP; Meyer DM; Engleman VW; Rico JG; Ruminski PG; Ornberg RL; Westlin WF; Nickols GA
J Endocrinol; 2000 Jun; 165(3):587-98. PubMed ID: 10828842
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.
Lark MW; Stroup GB; Dodds RA; Kapadia R; Hoffman SJ; Hwang SM; James IE; Lechowska B; Liang X; Rieman DJ; Salyers KL; Ward K; Smith BR; Miller WH; Huffman WF; Gowen M
J Bone Miner Res; 2001 Feb; 16(2):319-27. PubMed ID: 11204432
[TBL] [Abstract][Full Text] [Related]
10. Interferon gamma and calcitonin induce differential changes in cellular kinetics and morphology of osteoclasts in cultured neonatal mouse calvaria.
Klaushofer K; Hörandner H; Hoffmann O; Czerwenka E; König U; Koller K; Peterlik M
J Bone Miner Res; 1989 Aug; 4(4):585-606. PubMed ID: 2510468
[TBL] [Abstract][Full Text] [Related]
11. Echistatin is a potent inhibitor of bone resorption in culture.
Sato M; Sardana MK; Grasser WA; Garsky VM; Murray JM; Gould RJ
J Cell Biol; 1990 Oct; 111(4):1713-23. PubMed ID: 2211834
[TBL] [Abstract][Full Text] [Related]
12. S 12911-2 inhibits osteoclastic bone resorption in vitro.
Takahashi N; Sasaki T; Tsouderos Y; Suda T
J Bone Miner Res; 2003 Jun; 18(6):1082-7. PubMed ID: 12817762
[TBL] [Abstract][Full Text] [Related]
13. Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo.
Uy HL; Guise TA; De La Mata J; Taylor SD; Story BM; Dallas MR; Boyce BF; Mundy GR; Roodman GD
Endocrinology; 1995 Aug; 136(8):3207-12. PubMed ID: 7628353
[TBL] [Abstract][Full Text] [Related]
14. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment.
Mercer B; Markland F; Minkin C
J Bone Miner Res; 1998 Mar; 13(3):409-14. PubMed ID: 9525341
[TBL] [Abstract][Full Text] [Related]
15. The effects of parathyroid hormone (PTH) and PTH-related peptide on osteoclast resorption of bone slices in vitro: an analysis of pit size and the resorption focus.
Murrills RJ; Stein LS; Fey CP; Dempster DW
Endocrinology; 1990 Dec; 127(6):2648-53. PubMed ID: 2249618
[TBL] [Abstract][Full Text] [Related]
16. Rapid activation of the medullary bone osteoclast cell surface by parathyroid hormone.
Miller SC
J Cell Biol; 1978 Mar; 76(3):615-8. PubMed ID: 632322
[TBL] [Abstract][Full Text] [Related]
17. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.
Most W; Schot L; Ederveen A; van der Wee-Pals L; Papapoulos S; Löwik C
J Bone Miner Res; 1995 Oct; 10(10):1523-30. PubMed ID: 8686508
[TBL] [Abstract][Full Text] [Related]
18. Carboxyl-terminal parathyroid hormone fragments stimulate osteoclast-like cell formation and osteoclastic activity.
Kaji H; Sugimoto T; Kanatani M; Miyauchi A; Kimura T; Sakakibara S; Fukase M; Chihara K
Endocrinology; 1994 Apr; 134(4):1897-904. PubMed ID: 8137758
[TBL] [Abstract][Full Text] [Related]
19. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat.
Crippes BA; Engleman VW; Settle SL; Delarco J; Ornberg RL; Helfrich MH; Horton MA; Nickols GA
Endocrinology; 1996 Mar; 137(3):918-24. PubMed ID: 8603604
[TBL] [Abstract][Full Text] [Related]
20. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
O'Brien CA; Jilka RL; Fu Q; Stewart S; Weinstein RS; Manolagas SC
Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E784-93. PubMed ID: 15956054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
